nach oben

Erschienen in:

23.10.2017 | Erratum

Erratum to: Phase 1 study of darolutamide (ODM-201), a new-generation androgen receptor antagonist, in Japanese patients with metastatic castration-resistant prostate cancer

verfasst von: Nobuaki Matsubara, Hirofumi Mukai, Ako Hosono, Mai Onomura, Masaoki Sasaki, Yoko Yajima, Kensei Hashizume, Masanobu Yasuda, Miho Uemura, Christian Zurth

Erschienen in: Cancer Chemotherapy and Pharmacology | Ausgabe 6/2017

Einloggen, um Zugang zu erhalten

Excerpt

The author would like to correct the errors in the publication of the original article. The corrected details are given below for your reading. The original article was corrected. …

World Cancer Research Fund International/Continuous Update Project (2015) Prostate cancer statistics. http://www.wcrf.org/int/cancer-facts-figures/data-specificcancers/prostate-cancer-statistics. Accessed 14 Feb 2017

Foundation for Promotion of Cancer Research (2014) Cancer statistics in Japan—2014. http://ganjoho.jp/data/reg_stat/statistics/brochure/2014/cancer_statistics_2014_fig_E.pdf. Accessed 14 Feb 2017

Cancer Information Service, National Cancer Center. Vital Statistics in Japan. http://ganjoho.jp/en/professional/statistics/table_download.html. Accessed 15 May 2017

Hori M, Matsuda T, Shibata A, Katanoda K, Sobue T, Nishimoto H, Japan Cancer Surveillance Research Group (2015) Cancer incidence and incidence rates in Japan in 2009: a study of 32 population-based cancer registries for the Monitoring of Cancer Incidence in Japan (MCIJ) project. Jpn J Clin Oncol 45:884–891CrossRefPubMed

Sridhar SS, Freedland SJ, Gleave ME, Higano C, Mulders P, Parker C, Sartor O, Saad F (2014) Castration-resistant prostate cancer: from new pathophysiology to new treatment. Eur Urol 65:289–299CrossRefPubMed

Lassi K, Dawson NA (2010) Update on castrate-resistant prostate cancer: 2010. Curr Opin Oncol 22:263–267CrossRefPubMed

Kirby M, Hirst C, Crawford ED (2011) Characterising the castration-resistant prostate cancer population: a systematic review. Int J Clin Pract 65:1180–1192CrossRefPubMed

Beer TM, Armstrong AJ, Rathkopf D, Loriot Y, Sternberg CN, Higano CS, Iversen P, Evans CP, Kim CS, Kimura G, Miller K, Saad F, Bjartell AS, Borre M, Mulders P, Tammela TL, Parli T, Sari S, van Os S, Theeuwes A, Tombal B (2017) Enzalutamide in men with chemotherapy-naive metastatic castration-resistant prostate cancer: extended analysis of the phase 3 PREVAIL study. Eur Urol 71:151–154. doi:10.1016/j.eururo.2016.07.032 CrossRefPubMed

Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PF, Sternberg CN, Miller K, Logothetis CJ, Shore ND, Small EJ, Carles J, Flaig TW, Taplin ME, Higano CS, de Souza P, de Bono JS, Griffin TW, De Porre P, Yu MK, Park YC, Li J, Kheoh T, Naini V, Molina A, Rathkopf DE, COU-AA Investigators (2015) Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 16:152–160. doi:10.1016/s1470-2045(14)71205-7 CrossRefPubMed

10.

Agarwal N, Di Lorenzo G, Sonpavde G, Bellmunt J (2014) New agents for prostate cancer. Ann Oncol 25:1700–1709CrossRefPubMed

11.

Leibowitz-Amit R, Joshua AM (2012) Targeting the androgen receptor in the management of castration-resistant prostate cancer: rationale, progress, and future directions. Curr Oncol 19:S22–S31CrossRefPubMedPubMedCentral

12.

Pinto A (2014) Beyond abiraterone: new hormonal therapies for metastatic castration-resistant prostate cancer. Cancer Biol Ther 15:149–155CrossRefPubMed

13.

Fizazi K, Massard C, Bono P, Jones R, Kataja V, James N, Garcia JA, Protheroe A, Tammela TL, Elliott T, Mattila L, Aspegren J, Vuorela A, Langmuir P, Mustonen M, ARADES study group (2014) Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial. Lancet Oncol 15:975–985CrossRefPubMed

14.

Moilanen A, Riikonen R, Oksala R, Ravanti L, Aho E, Wohlfahrt G, Törmäkangas O, Kallio PJ (2013) ODM-201—new generation antiandrogen with excellent antiandrogenic and antitumor activity in nonclinical models of CRPC. Eur J Cancer 49:2869 (abstract) CrossRef

15.

Moilanen AM, Riikonen R, Oksala R, Ravanti L, Aho E, Wohlfahrt G, Nykanen PS, Tormakangas OP, Palvimo JJ, Kallio PJ (2015) Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies. Sci Rep 5:12007. doi:10.1038/srep12007 CrossRefPubMedPubMedCentral

16.

Fizazi K, Massard C, James ND, Culine S, Jones RH, Oksala R, Moilanen A, Aho E, Ravanti L, Kallio P (2013) ODM-201, a new generation androgen receptor inhibitor for castration-resistant prostate cancer: preclinical and phase I data. J Clin Oncol 31:65 (abstract) CrossRef

17.

Massard C, Penttinen HM, Vjaters E, Bono P, Lietuvietis V, Tammela TL, Vuorela A, Nykanen P, Pohjanjousi P, Snapir A, Fizazi K (2016) Pharmacokinetics, antitumor activity, and safety of ODM-201 in patients with chemotherapy-naive metastatic castration-resistant prostate cancer: an open-label phase 1 study. Eur Urol 69:834–840CrossRefPubMed

18.

Garcia JA, Kataja VV, James ND, Jones RH, Protheroe A, Massard C, Mattila L, Mustonen MVJ, Aspegren J, Fizazi K (2014) Bone and soft tissue response from a phase I/II study with ODM-201 in metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol 32:102 (abstract) CrossRef

19.

Tammela L, Massard C, Bono P, Langmuir P, Aspegren J, Vuorela A, Mustonen MVJ, Fizazi K (2014) Safety and efficacy of ODM-201 in chemotherapy and CYP17-inhibitor naïve patients: analysis of data from the ARADES and the ARAFOR trials. Eur Urol 13:e862 (abstract) CrossRef

20.

Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, Eisenberger MA, Higano C, Bubley GJ, Dreicer R, Petrylak D, Kantoff P, Basch E, Kelly WK, Figg WD, Small EJ, Beer TM, Wilding G, Martin A, Hussain M, Prostate Cancer Clinical Trials Working Group (2008) Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 26:1148–1159CrossRefPubMedPubMedCentral

21.

Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247CrossRefPubMed

Titel: Erratum to: Phase 1 study of darolutamide (ODM-201), a new-generation androgen receptor antagonist, in Japanese patients with metastatic castration-resistant prostate cancer
verfasst von: Nobuaki Matsubara
Hirofumi Mukai
Ako Hosono
Mai Onomura
Masaoki Sasaki
Yoko Yajima
Kensei Hashizume
Masanobu Yasuda
Miho Uemura
Christian Zurth
Publikationsdatum: 23.10.2017
Verlag: Springer Berlin Heidelberg
Erschienen in: Cancer Chemotherapy and Pharmacology / Ausgabe 6/2017
Print ISSN: 0344-5704
Elektronische ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-017-3433-3

Neu im Fachgebiet Onkologie

23.04.2024 | Medikamente in Schwangerschaft und Stillzeit | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Erratum to: Phase 1 study of darolutamide (ODM-201), a new-generation androgen receptor antagonist, in Japanese patients with metastatic castration-resistant prostate cancer

Excerpt

Neu im Fachgebiet Onkologie

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Stufenschema weist Prostatakarzinom zuverlässig nach

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2017

The potential usefulness of the Response Index in positron emission tomography assessing the therapeutic effect of pre-operative chemotherapy for advanced colorectal cancer

Ibrutinib does not prolong the corrected QT interval in healthy subjects: results from a thorough QT study

Randomized study of etirinotecan pegol versus irinotecan as second-line treatment for metastatic colorectal cancer

Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR-amplified, recurrent glioblastoma: results from a multi-center, international study

A triplet combination with capecitabine/oxaliplatin/irinotecan (XELOXIRI) plus cetuximab as first-line therapy for patients with metastatic colorectal cancer: a dose escalation study

Evaluation of the effect of new formulation, food, or a proton pump inhibitor on the relative bioavailability of the smoothened inhibitor glasdegib (PF-04449913) in healthy volunteers

Neu im Fachgebiet Onkologie

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Stufenschema weist Prostatakarzinom zuverlässig nach

Update Onkologie